Skip to main content

Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ: CRVS · IEX Real-Time Price · USD
6.19
+0.87 (16.35%)
After-hours:Sep 17, 2021 7:59 PM EDT
5.32
3.06 (135.40%)
At close: Sep 17, 4:00 PM
Market Cap160.78M
Revenue (ttm)n/a
Net Income (ttm)-5.78M
Shares Out42.25M
EPS (ttm)-0.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume252,822,104
Open3.78
Previous Close2.26
Day's Range2.26 - 5.80
52-Week Range1.86 - 5.80
Beta1.67
AnalystsStrong Buy
Price Target5.13 (-3.6%)
Est. Earnings DateOct 28, 2021

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and activate various immune cells, as Phase III clinical trial of CPI-006 for COVID-19. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lympho...

IndustryBiotechnology
IPO DateMar 23, 2016
CEORichard Miller
Employees42
Stock ExchangeNASDAQ
Ticker SymbolCRVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price forecast is 5.13, which is a decrease of -3.57% from the latest price.

Price Target
$5.13
(-3.57% downside)
Analyst Consensus: Strong Buy

News

Best Penny Stocks to Buy Right Now? 3 You Need to Know About

These penny stocks shot up today, are they worth watching or not? The post Best Penny Stocks to Buy Right Now?

Other symbols:CEIREED
13 hours ago - PennyStocks

What's Going On With Corvus Pharmaceuticals Stock Today?

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) is surging higher Friday on abnormally high volume. The stock might be trading higher following favorable data results by AstraZeneca PLC (NASDAQ: AZN) for pati...

13 hours ago - Benzinga

12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (CRVS) as Shares Rocket

Corvus Pharmaceuticals (CRVS) stock is rising higher on heavy trading volume Friday despite a lack of news from the company. The post 12 Things to Know About Biotech Penny Stock Corvus Pharmaceuticals (...

13 hours ago - InvestorPlace

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will partici...

1 week ago - GlobeNewsWire

4 Penny Stocks Insiders Are Buying

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...

Other symbols:HILHIPOLODE
3 weeks ago - Benzinga

Corvus Pharmaceuticals Announces IND Acceptance for Phase 1/1b Clinical Trial of CPI-818 in China

Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021 Corvus Partner Angel Pharmaceuticals Plans to Initiate Trial by Year-end 2021

1 month ago - GlobeNewsWire

Down 23.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Corvus (CRVS)

Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...

1 month ago - Zacks Investment Research

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

BURLINGAME, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial res...

1 month ago - GlobeNewsWire

Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Corvus (CRVS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re...

1 month ago - Zacks Investment Research

Corvus Pulls Plug On Mupadolimab COVID-19 Program With Candidate Now Prioritized In Oncology

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has discontinued its Phase 3 study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering infection and hospitalizations....

2 months ago - Benzinga

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectivenes...

Mupadolimab Phase 1/1b oncology clinical trial continues, with a focus on leveraging B cell activation and enhancement of anti-viral antibodies in an expansion cohort for patients with HPV+ (human papil...

2 months ago - GlobeNewsWire

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

BURLINGAME, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the Jefferies Virtua...

3 months ago - GlobeNewsWire

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

BURLINGAME, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has completed the sale of approximate...

4 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

BURLINGAME, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial re...

4 months ago - GlobeNewsWire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial re...

5 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Participation in Upcoming Investor Conferences

BURLINGAME, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company's management will partici...

6 months ago - GlobeNewsWire

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

6 months ago - Benzinga

Corvus Pharmaceuticals Announces Closing of Public Offering of Common Stock

BURLINGAME, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the completion of its previously announced u...

7 months ago - GlobeNewsWire

Why Corvus Pharmaceuticals, Prothena, CollPlant Are Moving Today

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-...

Other symbols:PRTACLGN
7 months ago - Benzinga

Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offeri...

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock

BURLINGAME, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public...

7 months ago - GlobeNewsWire

Corvus Pharmaceuticals Initiates Phase 3 Clinical Trial of CPI-006 for Patients with COVID-19

Novel immunotherapy approach designed to stimulate immune response by activating B cells to enhance polyclonal antibody production and potentially reduce hospitalization and progression to respiratory f...

7 months ago - GlobeNewsWire

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Ann...

Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas

9 months ago - GlobeNewsWire

Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & Exp...

Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b trial and pre-...

9 months ago - GlobeNewsWire

Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC An...

Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2

10 months ago - GlobeNewsWire